Overview

Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ambrisentan